research use only
Cat.No.S8367
| Related Targets | CFTR CRM1 CD markers AChR Calcium Channel Sodium Channel Potassium Channel GABA Receptor ATPase GluR |
|---|---|
| Other TRP Channel Inhibitors | 2-APB (2-Aminoethyl Diphenylborinate) SKF96365 AMG-517 GSK1016790A HC-030031 Capsazepine EIPA (L593754) SB705498 HC-067047 ML-SI3 |
| Cell Lines | Assay Type | Concentration | Incubation Time | Formulation | Activity Description | PMID |
|---|---|---|---|---|---|---|
| HEK293 | Function assay | 10 mins | Antagonist activity at rat TRPV4 expressed in HEK293 cells assessed as inhibition of GSK634775A-induced calcium influx preincubated for 10 mins followed by GSK634775A addition by Fura-4 dye based FLIPR assay, IC50=0.002μM | 28523109 | ||
| HEK293 | Function assay | 10 mins | Antagonist activity at human TRPV4 expressed in HEK293 cells assessed as inhibition of GSK634775A-induced calcium influx preincubated for 10 mins followed by GSK634775A addition by Fura-4 dye based FLIPR assay, IC50=0.04μM | 28523109 | ||
| HEK | Function assay | Antagonist activity at human TRPV4 channel transfected in HEK cells assessed as inhibition of GSK634775-evoked Ca2+ influx by FLIPR method, IC50=0.04μM | 31532662 | |||
| HEK | Function assay | Antagonist activity at human TRPV4 expressed in HEK cells assessed as inhibition of GSK634775-induced Ca2+ influx by FLIPR assay, IC50=0.05μM | 30500190 | |||
| Click to View More Cell Line Experimental Data | ||||||
| Molecular Weight | 691.62 | Formula | C37H38BrF3N4O |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 1336960-13-4 | -- | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | C1CCN(CC1)C2CCN(CC2)CC3=C(C4=C(C=C(C=C4)Br)N=C3C5=CC(=CC=C5)C(F)(F)F)C(=O)NC6(CC6)C7=CC=CC=C7 | ||
|
In vitro |
DMSO
: 100 mg/mL
(144.58 mM)
Ethanol : 40 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Targets/IC50/Ki |
rTRPV4
(Cell-free assay) 0.002 μM
hTRPV4
(Cell-free assay) 0.04 μM
|
|---|---|
| In vitro |
GSK2193874 is profiled against TRP channels and is selective against TRPV1, TRPA1, TRPC3, TRPC6, and TRPM8 (IC50 > 25 μM). Treatment of human umbilical vein endothelial cells (HUVECs) with this compound dose-dependently prevents the cellular contraction and detachment induced by TRPV4 activation with GSK1016790.
|
| In vivo |
The pharmacokinetic (PK) properties for GSK2193874 are evaluated in both rat and dog and found to have half-lives and oral exposure suitable for oral dosing in chronic animal models (Rat PK: iv CL = 7.3 mL/min/kg, po t1/2 = 10 h, %F =31. Dog PK: iv CL = 6.9 mL/min/kg, po t1/2 = 31 h, %F = 53). In addition, this compound shows no blood pressure or heart rate effect in rats when dose up to 30 mg/kg. It demonstrates to has the ability to improve pulmonary functions in a number of heart failure models. In both acute and chronic HF models, this compound pretreatment inhibits the formation of pulmonary edema and enhanced arterial oxygenation. TRPV4 blockade with this chemical provides protection against the development of pulmonary edema and the resulting deficits in arterial oxygenation in HF models in vivo. This compound preserves endothelial cell integrity and inhibits endothelial TRPV4 currents while providing protection from formation of pulmonary edema in isolated lungs and in HF models.
|
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.